Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients. Using a novel design, amantadine was studied in naïve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin. Patients enrolled in this randomized, placebo-c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2006-02, Vol.44 (2), p.275-282
Hauptverfasser:	Ferenci, Peter, Formann, Elisabeth, Laferl, Hermann, Gschwantler, Michael, Hackl, Franz, Brunner, Harald, Hubmann, Rainer, Datz, Christian, Stauber, Rudolf, Steindl-Munda, Petra, Kessler, Harald H., Klingler, Anton, Gangl, Alfred
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Amantadine Amantadine - therapeutic use Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Antiviral therapy Biological and medical sciences Chronic hepatitis C Disease Progression Double-Blind Method Drug Carriers Drug Therapy, Combination Female Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Genotype Genotype 1 Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - pathology Hepatitis C, Chronic - virology Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Quality of Life Recombinant Proteins Ribavirin - therapeutic use RNA, Viral - genetics Treatment Outcome Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients. Using a novel design, amantadine was studied in naïve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin. Patients enrolled in this randomized, placebo-controlled multicenter trial were stratified by single-dose interferon sensitivity (stratum I, 24-h HCV-RNA decline >1.4-log10; II, 0.8–1.39-log10; III,
ISSN:	0168-8278 1600-0641
DOI:	10.1016/j.jhep.2005.09.015